M&A Activity in the Healthcare Sector (CPH, CZO etc.) I believe there are more deals to come given that many Canadian helathcare names are very undervalued compared with the US-based peers.
For instance, I believe Cipher Pharmaceuticals (CPH) is a takeover target.
CPH has zero debt, profits and positive operating cash flow.
CPH's insiders own 40%, so their interests are aligned with shareholders'.
CPH also produces several dermatological products including its excellent creams for acne (i.e. its well-known Epuris has 41% market share in Canada).
CPH currently is dirt-cheap because it trades just 1.3 times its 2020 EBITDA.
And CPH has many levers to pull for revenue growth in 2021 because it has many promising drugs in the pipeline with very positive clinical trials to-date:
https://www.newswire.ca/news-releases/cipher-pharmaceuticals-reports-third-quarter-2020-financial-results-834044358.html
Another takeover target is Ceapro (CZO). Debt-free CZO is currently working on the production of an inhalable therapeutic for COVID-19. More to come very soon.